Medpace
MEDP
$512.79
+8.30%
Medpace Holdings, Inc. is a late-stage contract research organization (CRO) that provides full-service drug-development and clinical trial services primarily to small and midsize biotechnology, pharmaceutical, and medical device firms, operating within the healthcare sector's diagnostics and research industry. The company has established itself as a specialized player focused on the mid-market biotech segment, differentiating itself from larger CROs by offering an integrated, full-service model. The current investor narrative is dominated by significant stock volatility, as evidenced by a dramatic 55% price swing in February 2026, which has sparked debate over whether this reflects fundamental business performance, market structure dynamics, or a reaction to specific earnings results and guidance from the company and its peers.…
MEDP
Medpace
$512.79
Related headlines
Investment Opinion: Should I buy MEDP Today?
Rating: Hold. The investment thesis is that Medpace is a high-quality, high-growth business caught in a volatile correction; investors should wait for either a more attractive valuation entry point or clearer signs of technical stabilization before committing new capital.
Supporting Evidence: The stock trades at a forward P/E of 24.8x, which is a discount to its trailing P/E of 35.9x but still represents a premium given its PEG ratio of 1.82. While revenue growth is exceptional at 32% YoY and profitability is top-tier (98% ROE, 18% net margin), the stock's technical picture is weak, down 19% over six months with severe volatility. Analyst sentiment is mixed with limited coverage, and the stock trades 27% below its 52-week high, indicating broken momentum.
Risks & Conditions: The two biggest risks are 1) further multiple compression if growth slows, and 2) continued technical breakdown below the $416 support level. This Hold rating would upgrade to a Buy if the forward P/E compressed toward 20x (implying a price ~$480 based on $23.99 EPS) or if the stock establishes sustained support above its 200-day moving average. It would downgrade to a Sell if quarterly revenue growth decelerates below 25% or if the stock breaks below its 52-week low. Relative to its own high-growth profile and sector, the stock appears fairly valued to slightly overvalued, demanding perfection.
Sign up to view all
MEDP 12-Month Price Forecast
The outlook for MEDP is bifurcated between its stellar fundamentals and its treacherous price action. The base case (50% probability) of range-bound volatility around $500 is most likely, as the market digests its growth premium amidst sector uncertainty. The bull case depends on flawless execution reigniting investor enthusiasm, while the bear case is a real threat given the stock's demonstrated vulnerability to sentiment shifts. The stance would upgrade to Bullish on a confirmed breakout above $550 on strong volume, or downgrade to Bearish on a break below the $416 support level on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Medpace's 12-month outlook, with a consensus price target around $666.63 and implied upside of +30.0% versus the current price.
Average Target
$666.63
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$410 - $667
Analyst target range
Analyst coverage for MEDP is limited, with only 4 analysts providing estimates, indicating this is a mid-cap stock with less institutional research focus which can lead to higher volatility and less efficient price discovery. The consensus sentiment, inferred from recent institutional rating actions, appears mixed but leaning towards caution, with recent moves including an upgrade from Jefferies to 'Buy' and Barclays maintaining 'Underweight'. The average estimated EPS for the forward period is $23.99, with a range from $22.05 to $25.92, while estimated revenue averages $3.73 billion. The target price range implied by the EPS estimates, when combined with the forward PE, suggests a wide band of potential outcomes, reflecting significant uncertainty among analysts. The high-end EPS estimate of $25.92 likely assumes continued market share gains, sustained high demand for CRO services, and operational efficiency, while the low-end estimate of $22.05 may factor in potential competitive pressures, pricing challenges, or operational hiccups. The recent pattern of rating actions shows some divergence, with one upgrade and one maintained sell-equivalent rating in February 2026, signaling a lack of strong consensus and highlighting the stock's controversial nature following its volatile price action.
Bulls vs Bears: MEDP Investment Factors
The bull case for Medpace is anchored in its stellar fundamental performance: 32% revenue growth, near-100% ROE, and robust cash generation. However, the bear case highlights severe technical damage, extreme volatility, and a valuation that remains rich despite the recent correction. Currently, the bearish technical and sentiment factors hold stronger near-term evidence, as the stock's violent price action and lack of analyst conviction outweigh the strong fundamentals. The single most important tension in the investment debate is whether the company's exceptional growth and profitability can sustainably justify its premium valuation (PEG 1.82) in the face of demonstrated market skepticism and high volatility.
Bullish
- Exceptional Revenue Growth: Q4 2025 revenue grew 32.03% YoY to $708.45M, demonstrating strong demand for its CRO services. Sequential quarterly growth from $558.57M in Q1 to $708.45M in Q4 shows consistent execution.
- Outstanding Profitability & ROE: Q4 2025 net margin was 19.07%, and the trailing 12-month ROE is an exceptional 98.27%. This indicates highly efficient capital deployment and a scalable, profitable business model.
- Strong Free Cash Flow Generation: The company generated $708.69M in TTM free cash flow, providing ample liquidity for growth and operations. This is supported by a moderate debt-to-equity ratio of 0.55.
- Attractive Forward Valuation: The forward P/E of 24.79x represents a significant discount to the trailing P/E of 35.91x, implying the market expects ~45% EPS growth. This offers a better entry point for a high-growth company.
Bearish
- Extreme Stock Volatility & Weakness: The stock is down 19.03% over six months and 19.41% YTD, with a 55% single-day swing in February 2026. A beta of 1.183 confirms it is 18% more volatile than the market, posing significant risk.
- High Valuation Premiums Persist: Despite the correction, valuation multiples remain elevated with a P/S of 6.40x and a PEG ratio of 1.82. This leaves the stock vulnerable to multiple compression if growth slows even slightly.
- Limited Analyst Coverage & Mixed Sentiment: Only 4 analysts cover the stock, leading to less efficient price discovery. Recent ratings include an 'Underweight' from Barclays, indicating a lack of strong consensus and potential fundamental concerns.
- Recent Sharp Sell-Offs Undermine Confidence: The stock experienced dramatic declines in February and again in April 2026 (from ~$520 to ~$393), breaking key technical support. This pattern suggests persistent selling pressure and weak investor conviction.
MEDP Technical Analysis
The prevailing price trend for MEDP is a volatile downtrend from its highs, with the stock down 19.03% over the past six months, despite a strong 52.04% gain over the past year. The current price of $460.2 sits approximately 50% above its 52-week low of $301.9 but remains 27% below its 52-week high of $628.916, indicating it is trading in the lower-middle portion of its annual range and has experienced a significant correction from peak levels. This positioning suggests the stock is in a recovery phase from a sharp sell-off, presenting a potential value opportunity if fundamentals hold, but also carries the risk of further decline if the downtrend persists. Recent short-term momentum shows signs of stabilization and recovery, with the stock up 9.59% over the past month, which contrasts sharply with its negative 6-month and year-to-date performance of -19.41%. This positive 1-month trend diverging from the longer-term downtrend could signal the beginning of a mean reversion or a temporary relief rally following the severe decline witnessed in February and April 2026. The stock's relative strength over the past month of +8.85% versus the SPY further supports this short-term bullish momentum, though it remains weak on a 3-month basis at -13.44%. Key technical support is firmly established at the 52-week low of $301.9, while immediate resistance lies at the recent recovery high near $520 and the ultimate ceiling at the 52-week high of $628.916. A sustained breakout above the $520 level would signal a stronger recovery is underway, while a breakdown below the $416 low from February could trigger a retest of the 52-week low. The stock's beta of 1.183 indicates it is approximately 18% more volatile than the broader market, which is consistent with the observed large price swings and is a critical factor for risk-aware investors considering position sizing.
Beta
1.18
1.18x market volatility
Max Drawdown
-36.6%
Largest decline past year
52-Week Range
$306-$629
Price range past year
Annual Return
+62.6%
Cumulative gain past year
| Period | MEDP Return | S&P 500 |
|---|---|---|
| 1m | +18.5% | -1.7% |
| 3m | +9.9% | +13.7% |
| 6m | -9.7% | +6.2% |
| 1y | +62.6% | +20.8% |
| ytd | -10.2% | +7.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MEDP Fundamental Analysis
Medpace exhibits a robust revenue growth trajectory, with Q4 2025 revenue of $708.45 million representing a substantial 32.03% year-over-year increase. This growth has been consistent on a sequential quarterly basis throughout 2025, with revenue climbing from $558.57 million in Q1 to $708.45 million in Q4, indicating strong demand for its CRO services. The revenue segment data shows the Metabolic therapeutic area is the largest contributor at $249.81 million, followed by Oncology at $195.92 million, suggesting diversified but concentrated exposure to high-growth therapeutic areas which supports the overall growth narrative. The company is highly profitable, with Q4 2025 net income of $135.13 million and a net margin of 19.07%. Gross margin for the quarter was 28.98%, while the operating margin was a healthy 21.64%. Profitability has shown some quarterly variability, with net margins ranging from a high of 20.52% in Q1 2025 to 14.96% in Q2 2025, but the overall trend remains strong, supported by the company's scalable operating model. The net margin of 17.83% from valuation data is solid for the CRO industry, reflecting efficient operations. Medpace maintains a strong balance sheet and cash flow profile, with a debt-to-equity ratio of 0.55 indicating moderate leverage and a current ratio of 0.74 showing adequate short-term liquidity. The company generated substantial free cash flow of $708.69 million on a trailing twelve-month basis, demonstrating its ability to fund operations and growth internally. The exceptional return on equity of 98.27% highlights highly efficient use of shareholder capital, though this is partly amplified by the moderate debt level and the company's asset-light business model.
Quarterly Revenue
$708450000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$708687000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MEDP Overvalued?
Given Medpace's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 35.91x and a forward PE of 24.79x based on estimated EPS. The significant gap between the trailing and forward multiples implies the market expects robust earnings growth, with the forward PE discount suggesting anticipated EPS expansion of approximately 45% if the price holds steady. Compared to sector averages, Medpace's valuation presents a mixed picture. Its trailing PE of 35.91x is difficult to compare directly without a provided industry average, but its Price-to-Sales ratio of 6.40x and EV-to-Sales of 4.73x offer alternative perspectives. The company's premium valuation is likely justified by its superior growth profile, with 32% YoY revenue growth, and high profitability metrics like a 17.8% net margin and 98.3% ROE, which are exceptional for the CRO industry and command a higher multiple. Historically, the stock's current trailing PE of 35.91x sits below its recent peak multiples observed in late 2025, such as the 50.84x PB ratio in Q3 2025, but above levels seen in early 2024 (e.g., 21.96x PE in Q4 2024). This places the valuation in the upper-mid range of its own historical band, suggesting the market is pricing in sustained high growth and profitability, but not at the most extreme optimistic levels seen previously. The PEG ratio of 1.82 indicates the stock is priced at a premium relative to its growth rate.
PE
35.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 18x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Medpace's primary financial risk is its premium valuation, which demands flawless execution. A forward P/E of 24.8x and a PEG ratio of 1.82 imply high expectations for sustained 30%+ revenue growth. Any deceleration could trigger significant multiple compression. While profitability is strong, quarterly net margin volatility (ranging from 15% to 21%) indicates potential sensitivity to project mix or cost pressures. The company's focus on mid-market biotech clients, while a differentiator, could expose it to client concentration risk if a few key sponsors reduce R&D spending.
Market & Competitive Risks: The stock's beta of 1.183 makes it highly sensitive to market downturns, particularly for growth stocks. The CRO industry is competitive, and Medpace's premium valuation (P/S 6.4x) could compress if larger peers compete more aggressively on price or if sector-wide funding for biotech clients tightens. The recent news highlighting 'big stock swings' and its inclusion in 'large-cap losers' lists underscores its susceptibility to sentiment-driven sell-offs, as seen in the 55% intraday swing in February 2026, which was attributed to market structure and liquidity issues rather than a fundamental collapse.
Worst-Case Scenario: A worst-case scenario involves a combination of a growth scare (e.g., quarterly revenue growth falling below 20%), a broader market sell-off impacting high-beta stocks, and a loss of investor confidence leading to a derating towards its historical valuation lows. This could see the stock re-test its 52-week low of $301.9, representing a downside of approximately -34% from the current price of ~$460. The stock has already demonstrated a capacity for severe drawdowns, with a -36.61% max drawdown in the provided period, indicating this level of loss is within the realm of recent historical precedent.
FAQ
The key risks are: 1) Valuation & Volatility Risk: High multiples (PEG 1.82) and beta (1.18) make the stock prone to sharp declines if growth falters or market sentiment sours, as seen in the 55% price swing in February. 2) Execution Risk: The company must maintain >30% revenue growth to justify its premium; any slowdown could trigger a severe derating. 3) Competitive/Market Risk: As a mid-market CRO, it faces competition from larger players and depends on biotech R&D funding. 4) Sentiment & Liquidity Risk: Limited analyst coverage (4 firms) can lead to exaggerated moves and inefficient price discovery.
The 12-month forecast presents three scenarios. The Base Case (50% probability) targets $480-$550, assuming MEDP meets analyst EPS estimates of ~$24.00 and trades at a ~25x forward P/E. The Bull Case (30% probability) targets $595-$650, requiring sustained >30% growth and a re-rating. The Bear Case (20% probability) targets $302-$400, involving a growth scare and a test of the 52-week low. The base case is most likely, centered on the analyst average target implied by a forward P/E in the mid-20s, but the wide range reflects the stock's high volatility and binary sentiment.
MEDP appears fairly valued to slightly overvalued based on a blended assessment. Its forward P/E of 24.8x is a discount to its trailing P/E of 35.9x, reflecting expected earnings growth. However, a PEG ratio of 1.82 suggests the market is already pricing in robust future growth. Compared to sector averages, its P/S of 6.40x and EV/Sales of 4.73x are likely at a premium, justified by its superior growth and profitability metrics. The valuation implies the market expects sustained high-20s growth; any shortfall would likely lead to multiple compression.
MEDP is a Hold, not a clear Buy at current levels. For investors with a high risk tolerance and a long-term horizon, the company's exceptional fundamentals (32% revenue growth, 98% ROE) are compelling. However, the stock's extreme volatility (beta 1.18, -19% over 6 months) and premium valuation (PEG 1.82) present significant near-term risk. It could be a good buy on a further pullback towards the $400-$420 support zone, where the risk/reward improves materially. Patient investors should wait for either a better price or clearer technical stabilization.
MEDP is primarily suitable for long-term investors (3-5 year horizon) who can weather extreme volatility to capture its underlying growth story. The stock's high beta (1.18) and history of violent swings make it a poor candidate for short-term trading, as technical patterns are frequently disrupted. The lack of a dividend also removes an income component. Long-term holders can potentially benefit from the company's scalable business model and high ROE if execution remains strong. A minimum holding period of 2-3 years is suggested to smooth out the volatility and allow fundamentals to drive returns.